Behavioural management of the triggers of recurrent headache: Avoidance versus coping

Not Applicable

Recruiting

• Conditions: Migraines; Tension-type headaches; Other - Conditions of unknown or disputed aetiology (such as chronic fatigue syndrome/myalgic encephalomyelitis); Neurological - Other neurological disorders

• Registration Number: ACTRN12610000393055
• Lead Sponsor: Professor Paul Martin (Principal Investigator)

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2010-05-17
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 180

Inclusion Criteria

(i) diagnosed as either ‘migraine without aura’, ‘probable migraine without aura’, ‘typical aura with migraine headache’, ‘probable migraine with aura’, ‘chronic migraine’, ‘frequent episodic tension-type headache’, probable frequent episodic tension-type headache’, ‘chronic tension-type headache’, ‘probable ergotamine-overuse headache’, ‘probable triptan -overuse headache’, ‘probable analgesic -overuse headache’, ‘probable opioid-overuse headache’, ‘probable combination analgesic-overuse headache’, ‘headache probably attributed to overuse of acute medication combinations’, ‘headache probably attributed to other medication overuse- Headache Classification Subcommittee of the International Headache Society (IHS), 2005; (ii) minimum of 6 headache days per month; (iii) minimum headache chronicity of 12 months, and pattern of headache symptoms stable over last 6 months.

Exclusion Criteria

(i) pregnant, planning pregnancy during trial period or lactating; (ii) currently taking headache prophylactic medication (one month wash-out period required); (iii) currently receiving psychological or psychiatric treatment.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Self-monitoring diary of daily medication consumption.[Baseline (for 4 weeks prior to commencement of treatment), throughout treatment, immediately post treatment (for 4 weeks), 4 and 12 months post treatment (for 4 weeks each time). 'Throughout treatment' means monitoring this on a daily basis over the 8 weeks of treatment.];Self-monitoring diary of daily headache triggers presence.[Baseline (for 4 weeks prior to commencement of treatment), throughout treatment (for 8 weeks), immediately post treatment (for 4 weeks), 4 and 12 months post treatment (for 4 weeks each time).];Self-monitoring diary of daily headache severity.[Baseline (for 4 weeks prior to commencement of treatment), throughout treatment, immediately post treatment (for 4 weeks), 4 and 12 months post treatment (for 4 weeks each time). 'Throughout treatment' means monitoring this on a daily basis over the 8 weeks of treatment.]

Secondary Outcome Measures

Name	Time	Method
Headache Self-Efficacy Scale (HSESv2).[Baseline, immediately post treatment, 4 and 12 months post treatment.];Headache-Specific Locus of Control (HSLC).[Baseline, immediately post treatment, 4 and 12 months post treatment.];Headache Disability Inventory (HDI).[Baseline, immediately post treatment, 4 and 12 months post treatment.];Short-Form Health Survey (SF-36v2).[Baseline, immediately post treatment, 4 and 12 months post treatment.];Personal Wellbeing Index (PWI).[Baseline, immediately post treatment, 4 and 12 months post treatment.];Headache Triggers Avoidance Questionnaire (HTAQ).[Baseline, immediately post treatment, 4 and 12 months post treatment.]